Passage BIO (PASG) Other Non-Current Assets (2019 - 2026)
Passage BIO (PASG) posted quarterly Other Non-Current Assets of $244000.0 for Q1 2026, down 10.95% year-over-year from $274000.0 in Q1 2025, and little changed quarter-over-quarter from $244000.0 in Q4 2025.
Passage BIO (PASG) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Passage BIO's Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $244000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 10.95% year-over-year to $244000.0; the TTM figure through Mar 2026 stood at $244000.0 (down 10.95% YoY), while the FY2025 annual figure was $244000.0, down 47.3% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $244000.0, roughly flat from $244000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $5.7 million in Q1 2022, with the low at $244000.0 in Q4 2025.
- The 5-year median for Other Non-Current Assets is $433000.0 (2023), against an average of $1.5 million.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets plunged 92.43% in 2023, then soared 52.89% in 2024.
- Passage BIO's Other Non-Current Assets stood at $4.3 million in 2022, then slumped by 89.85% to $433000.0 in 2023, then gained by 6.93% to $463000.0 in 2024, then sank by 47.3% to $244000.0 in 2025, then changed by 0.0% to $244000.0 in 2026.
- Business Quant data shows PASG's Other Non-Current Assets at $244000.0 in Q1 2026, $244000.0 in Q4 2025, and $270000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | Passage BIO | 15.05 Mn | 15.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 244,000.00 |
| Dec 31, 2025 | 244,000.00 |
| Sep 30, 2025 | 270,000.00 |
| Jun 30, 2025 | 270,000.00 |
| Mar 31, 2025 | 274,000.00 |
| Dec 31, 2024 | 463,000.00 |
| Sep 30, 2024 | 463,000.00 |
| Jun 30, 2024 | 516,000.00 |
| Mar 31, 2024 | 662,000.00 |
| Dec 31, 2023 | 433,000.00 |
| Sep 30, 2023 | 433,000.00 |
| Jun 30, 2023 | 433,000.00 |
| Mar 31, 2023 | 433,000.00 |
| Dec 31, 2022 | 4.27 Mn |
| Sep 30, 2022 | 4.72 Mn |
| Jun 30, 2022 | 5.22 Mn |
| Mar 31, 2022 | 5.72 Mn |
| Dec 31, 2021 | 6.20 Mn |
| Sep 30, 2021 | 6.71 Mn |
| Jun 30, 2021 | 7.21 Mn |